CoChat
Sign Up
Cited by 83Liver Diseases and ImmunityMicroRNA in disease regulationGut microbiota and health

Distinct MicroRNAs Expression Profile in Primary Biliary Cirrhosis and Evaluation of miR 505-3p and miR197-3p as Novel Biomarkers

Open access
Ninomiya, Masashi, Kondo, Yasuteru, Funayama, Ryo, Nagashima, Takeshi, Kogure, Takayuki, Kakazu, Eiji, Kimura, Osamu, Ueno, Yoshiyuki +2 more·2013·PLoS ONE
DOI 10.1371/journal.pone.0066086PMC PMC3680413
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND AND AIMS: MicroRNAs are small endogenous RNA molecules with specific expression patterns that can serve as biomarkers for numerous diseases. However, little is known about the expression profile of serum miRNAs in PBC. METHODS: First, we employed Illumina deep sequencing for the initial screening to indicate the read numbers of miRNA expression in 10 PBC, 5 CH-C, 5 CH-B patients and 5 healthy controls. Comparing the differentially expressed miRNAs in the 4 groups, analysis of variance was performed on the number of sequence reads to evaluate the statistical significance. Hierarchical clustering was performed using an R platform and we have found candidates for specific miRNAs in the PBC patients. Second, a quantitative reverse transcription PCR validation study was conducted in 10 samples in each group. The expression levels of the selected miRNAs were presented as fold-changes (2(-ΔΔCt)). Finally, computer analysis was conducted to predict target genes and biological functions with MiRror 2.0 and DAVID v6.7. RESULTS: We obtained about 12 million 32-mer short RNA reads on average per sample and the mapping rates to miRBase were 16.60% and 81.66% to hg19. In the statistical significance testing, the expression levels of 81 miRNAs were found to be differentially expressed in the 4 groups. The heat map and hierarchical clustering demonstrated that the miRNA profiles from PBC clustered with those of CH-B, CH-C and healthy controls. Additionally, the circulating levels of hsa-miR-505-3p, 197-3p, and 500a-3p were significantly decreased in PBC compared with healthy controls and the expression levels of hsa-miR-505-3p, 139-5p and 197-3p were significantly reduced compared with the viral hepatitis group. CONCLUSIONS: Our results indicate that sera from patients with PBC have a unique miRNA expression profile and that the down-regulated expression of hsa-miR-505-3p and miR-197-3p can serve as clinical biomarkers of PBC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0066086

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • miR-505-3p is known to have a tumor suppressor role.

    “miR-505-3p is one of the miR types known to have a tumor suppressor role (14)(15)(16)(17).”

    From Functional interaction between miR-505-3p and miR-21 contributes to GBM suppression (2026) · cites this paper as [16]

    The Discussion identifies reduced serum miR-505-3p as a potential biomarker for primary biliary cirrhosis, but does not describe it as a tumor suppressor. Searches for “miR-505-3p tumor suppressor” and “tumor suppressor cancer miR-505” found no passage addressing that role. Page numbers were not available in our copy. (LLM, conf=0.73)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 51

  1. [1]Lau NC, Lim LP, Weinstein EG, Bartel DP (2001) An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294: 858– 862. 11679671
  2. [2]Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T (2001) Identification of novel genes coding for small expressed RNAs. Science 294: 853– 858. 11679670
  3. [3]Lee RC, Ambros V (2001) An extensive class of small RNAs in Caenorhabditis elegans. Science 294: 862– 864. 11679672
  4. [4]Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281– 297. 14744438
  5. [5]Chen X, Ba Y, Ma L, Cai X, Yin Y, et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research 18: 997– 1006. 18766170
  6. [6]Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834– 838. 15944708
  7. [7]Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, et al (2011) Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 106: 1663– 1669. 21606975
  8. [8]Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, et al (2010) Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 56: 1830– 1838. 20930130
  9. [9]Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L (2011) Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease. PLoS One 6: e23937. 21886843 PMC3160337
  10. [10]Morita K, Taketomi A, Shirabe K, Umeda K, Kayashima H, et al (2011) Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int 31: 474– 484. 21199296
  11. [11]Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, et al (2010) Serum microRNA Profiles Serve as Novel Biomarkers for HBV Infection and Diagnosis of HBV-Positive Hepatocarcinoma. Cancer Research 70: 9798– 9807. 21098710
  12. [13]Gershwin ME, Mackay IR, Sturgess A, Coppel RL (1987) Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 138: 3525– 3531. 3571977
  13. [14]Coppel RL, McNeilage LJ, Surh CD, Van de Water J, Spithill TW, et al (1988) Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. Proc Natl Acad Sci U S A 85: 7317– 7321. 3174635 PMC282177
  14. [16]Begovich AB, Klitz W, Moonsamy PV, Van de Water J, Peltz G, et al (1994) Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis. Tissue Antigens 43: 71– 77. 8016844
  15. [17]Donaldson PT, Baragiotta A, Heneghan MA, Floreani A, Venturi C, et al (2006) HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study. Hepatology 44: 667– 674. 16941709
  16. [18]Onishi S, Sakamaki T, Maeda T, Iwamura S, Tomita A, et al (1994) DNA typing of HLA class II genes; DRB1*0803 increases the susceptibility of Japanese to primary biliary cirrhosis. J Hepatol 21: 1053– 1060. 7699227
  17. [19]Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, et al (2009) Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 360: 2544– 2555. 19458352 PMC2857316
  18. [20]Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, et al (2011) Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 43: 329– 332. 21399635 PMC3071550
  19. [21]Hirschfield G, Invernizzi P (2011) Progress in the Genetics of Primary Biliary Cirrhosis. Seminars in Liver Disease 31: 147– 156. 21538281
  20. [23]Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, et al (2009) Primary biliary cirrhosis. Hepatology 50: 291– 308. 19554543
  21. [24]Corpechot C, Poupon R (2007) Geotherapeutics of primary biliary cirrhosis: Bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom. Hepatology 46: 963– 965. 17894325
  22. [25]Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, et al (1996) Natural history of early primary biliary cirrhosis. Lancet 348: 1399– 1402. 8937278
  23. [26]Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, et al (2008) Serum microRNAs are promising novel biomarkers. PLoS One 3: e3148. 18773077 PMC2519789
  24. [27]Martin M (2011) Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet journal 17: 10– 12.
  25. [28]Robinson MD, Oshlack A (2010) A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biology 11: R25. 20196867 PMC2864565
  26. [29]Balaga O, Friedman Y, Linial M (2012) Toward a combinatorial nature of microRNA regulation in human cells. Nucleic Acids Res 40: 9404– 9416. 22904063 PMC3479204
  27. [30]Juran BD, Lazaridis KN (2010) Update on the genetics and genomics of PBC. J Autoimmun 35: 181– 187. 20638243 PMC2956841
  28. [31]Zhang R, Peng Y, Wang W, Su B (2007) Rapid evolution of an X-linked microRNA cluster in primates. Genome Res 17: 612– 617. 17416744 PMC1855169
  29. [32]Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences 105: 10513– 10518. PMC2492472 18663219
  30. [33]Ai J, Zhang R, Li Y, Pu J, Lu Y, et al (2010) Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochemical and Biophysical Research Communications 391: 73– 77. 19896465
  31. [34]Chim SSC, Shing TKF, Hung ECW, Leung Ty, Lau Tk, et al (2008) Detection and Characterization of Placental MicroRNAs in Maternal Plasma. Clinical Chemistry 54: 482– 490. 18218722
  32. [35]Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DGN, et al (2011) Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54: 1767– 1776. 22045675
  33. [37]Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, et al (2010) Circulating microRNAs in plasma of patients with gastric cancers. British Journal of Cancer 102: 1174– 1179. 20234369 PMC2853097
  34. [38]Kong X, Du Y, Wang G, Gao J, Gong Y, et al (2010) Detection of Differentially Expressed microRNAs in Serum of Pancreatic Ductal Adenocarcinoma Patients: miR-196a Could Be a Potential Marker for Poor Prognosis. Digestive Diseases and Sciences 56: 602– 609. 20614181
  35. [39]Silva J, Garcia V, Zaballos A, Provencio M, Lombardia L, et al (2010) Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. European Respiratory Journal 37: 617– 623. 20595154
  36. [40]Li M, Marin-Muller C, Bharadwaj U, Chow K-H, Yao Q, et al (2008) MicroRNAs: Control and Loss of Control in Human Physiology and Disease. World Journal of Surgery 33: 667– 684. PMC2933043 19030926
  37. [41]Berg CP, Stein GM, Keppeler H, Gregor M, Wesselborg S, et al (2007) Apoptosis-associated antigens recognized by autoantibodies in patients with the autoimmune liver disease primary biliary cirrhosis. Apoptosis 13: 63– 75. 18060504
  38. [42]Liang Y, Yang Z, Li C, Zhu Y, Zhang L, et al (2008) Characterisation of TNF-related apoptosis-inducing ligand in peripheral blood in patients with primary biliary cirrhosis. Clinical and Experimental Medicine 8: 1– 7. 18385934
  39. [43]Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25– 29. 10802651 PMC3037419
  40. [44]Nakagome Y, Ueno Y, Kogure T, Fukushima K, Moritoki Y, et al (2007) Autoimmune cholangitis in NOD.c3c4 mice is associated with cholangiocyte-specific Fas antigen deficiency. J Autoimmun 29: 20– 29. 17482429
  41. [45]Singh R, Bullard J, Kalra M, Assefa S, Kaul AK, et al (2011) Status of bacterial colonization, Toll-like receptor expression and nuclear factor-kappa B activation in normal and diseased human livers. Clinical Immunology 138: 41– 49. 20940109
  42. [46]Kyriakou DS, Alexandrakis MG, Zachou K, Passam F, Stathakis NE, et al (2003) Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol 39: 679– 685. 14568247
  43. [47]Maglott D, Ostell J, Pruitt KD, Tatusova T (2010) Entrez Gene: gene-centered information at NCBI. Nucleic Acids Research 39: D52– D57. 21115458 PMC3013746
  44. [48]Kozomara A, Griffiths-Jones S (2010) miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Research 39: D152– D157. 21037258 PMC3013655
  45. [49]Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society 57: 289– 300.
  46. [51]Friedman Y, Naamati G, Linial M (2010) MiRror: a combinatorial analysis web tool for ensembles of microRNAs and their targets. Bioinformatics 26: 1920– 1921. 20529892
  47. [52]Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3. 12734009
  48. [53]Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, et al (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1: 431– 435. 7308988
  49. [54]Ludwig J, Dickson ER, McDonald GS (1978) Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 379: 103– 112. 150690
  50. [55]Scheuer P (1967) Primary biliary cirrhosis. Proceedings of the Royal Society of Medicine 60: 1257– 1260. 6066569 PMC1901478
  51. [56]Ward JH (1963) Hierarchical Grouping to Optimize an Objective Function. Journal of the American Statistical Association 58: 236– 244.

Cited by

Sorted by citations

Authors
Ninomiya, M., Kondo, Y., Funayama, R., Nagashima, T., Kogure, T., Kakazu, E., Kimura, O., Ueno, Y., Nakayama, K., & Shimosegawa, T.
Affiliations
  • Tohoku University Hospital (JP)
  • Tohoku University (JP)
  • Yamagata University (JP)
Corresponding author
Kondo, Yasuteru
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2013-06-12
Volume
8
Issue
6
Pages
e66086
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0066086
PMC
PMC3680413
OpenAlex
W2041990656
Cited by
83
References
4
Citations by year
2026: 1 · 2024: 2 · 2023: 5 · 2022: 4 · 2021: 4 · 2020: 3 · 2019: 6 · 2018: 11 · 2017: 12 · 2016: 15 · 2015: 10 · 2014: 9 · 2013: 1
FWCI
7.26
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
Japan Society for the Promotion of Science (24700951, 23790765)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
primary biliary cirrhosis, microRNA expression profiles, serum microRNA, miR-197-3p, circulating biomarkers, viral hepatitis, differentially expressed miRNAs, miRNA target prediction
MeSH terms
Aged, Female, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Biomarkers, Cluster Analysis, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, MicroRNAs, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review